# Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

> **NCT06643819** · PHASE3 · RECRUITING · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 324 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Sacubitril∙Valsartan(dose maintenance)
- **DRUG:** Sacubitril∙Valsartan(dose increasing)
- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT06643819
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-14
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643819, "Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06643819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*